Drug intelligence / Profile preview

ISOT-AMP

Development stage: Preclinical
Lead developer: IsoThrive
Modality: Small Molecules

Overview

ISOT-AMP is a small molecule drug under development by IsoThrive for the treatment of colorectal cancer. As of March 2025, it is in preclinical development and has not yet entered clinical trials. The specific mechanism of action, molecular target(s), and detailed pharmacology have not been publicly disclosed. There are no indications that it is a combination product or related to other known drugs such as amphetamine or its analogs. The developer and originator organization is IsoThrive.

Beyond the preview

Go deeper on ISOT-AMP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISOT-AMP.

Explore the full profile